High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity

Progress in Cardiovascular Diseases

Volumn 58, Issue 1, 2015, Pages 32-40

  Rohatgi, Anand ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cholesterol efflux; Coronary disease; Function; HDL; Heart disease; Lipoprotein

Indexed keywords

ABC TRANSPORTER A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHEMICAL PARAMETERS; CHOLESTEROL EFFLUX CAPACITY; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; EX VIVO STUDY; FOAM CELL; HUMAN; LIFESTYLE MODIFICATION; LIPOPROTEIN METABOLISM; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVERSE CHOLESTEROL TRANSPORT; RISK ASSESSMENT; RISK FACTOR; ANIMAL; ATHEROSCLEROSIS; BLOOD; COMPLICATION; DYSLIPIDEMIAS; METABOLISM; MORTALITY; PROGNOSIS; RISK REDUCTION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BIOMARKERS; CHOLESTEROL, HDL; DYSLIPIDEMIAS; HUMANS; MACROPHAGES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84937637879     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.05.004     Document Type: Article

References (48)

1. Stone N.J., Robinson J., Lichtenstein A.H., et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013.
2. Kathiresan S., Otvos J.D., Sullivan L.M., et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006, 113:20-29.
3. Waterworth D.M., Ricketts S.L., Song K., et al. Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease. Arterioscler Thromb Vasc Biol 2010, 30:2264-2276.
4. Edmondson A.C., Brown R.J., Kathiresan S., et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest 2009, 119:1042-1050.
5. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med 2014, 371:203-212.
6. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
7. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
8. Schwartz G.G., Olsson A.G., Abt M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012, 367:2089-2099.
9. Rader D.J., Alexander E.T., Weibel G.L., Billheimer J., Rothblat G.H. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009, (50 Suppl.):S189-S194.
10. Mineo C., Shaul P.W. Regulation of signal transduction by HDL. J Lipid Res 2013, 54:2315-2324.
11. Rader D.J., Hovingh G.K. HDL and cardiovascular disease. Lancet 2014, 384:618-625.
12. Rothblat G.H., de la Llera-Moya M., Favari E., Yancey P.G., Kellner-Weibel G. Cellular cholesterol flux studies: methodological considerations. Atherosclerosis 2002, 163:1-8.
13. Li X.M., Tang W.H., Mosior M.K., et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013, 33:1696-1705.
14. Fielding C.J., Fielding P.E. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. Proc Natl Acad Sci U S A 1981, 78:3911-3914.
15. Low H., Hoang A., Forbes J., et al. Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models. Diabetologia 2012, 55:2513-2521.
16. Syvänne M., Castro G., Dengremont C., et al. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis 1996, 127:245-253.
17. Linsel-Nitschke P., Jansen H., Aherrarhou Z., et al. Macrophage cholesterol efflux correlates with lipoprotein subclass distribution and risk of obstructive coronary artery disease in patients undergoing coronary angiography. Lipids Health Dis 2009, 8.
18. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
19. Cholesterol Efflux Capacity and Atherosclerosis. N Engl J Med 2011, 364:1472-1475.
20. Khera A.V., Rader D.J. Cholesterol efflux capacity: full steam ahead or a bump in the road?. Arterioscler Thromb Vasc Biol 2013, 33:1449-1451.
21. Rohatgi A., Khera A., Berry J.D., et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014, 371:2383-2393.
22. Saleheen D, Scott R, Javad S, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015 May 26. pii: S2213-8587(15)00126-6. [Epub ahead of print]. doi:10.1016/S2213-8587(15)00126-6.
23. Yamamoto S., Yancey P.G., Ikizler T.A., et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 2012, 60:2372-2379.
24. Kaseda R., Jabs K., Hunley T.E., et al. Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism 2015, 64:263-273.
25. Shroff R., Speer T., Colin S., et al. HDL in Children with CKD Promotes Endothelial Dysfunction and an Abnormal Vascular Phenotype. J Am Soc Nephrol 2014, 25:2658-2668.
26. Dullaart R.P.F., Groen A.K., Dallinga-Thie G.M., Rd Vries, Sluiter W.J., Av Tol Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol. Eur J Endocrinol 2008, 158:53-60.
27. Dullaart R.P.F., Annema W., de Boer J.F., Tietge U.J.F. Pancreatic β-cell function relates positively to HDL functionality in well-controlled Type 2 diabetes mellitus. Atherosclerosis 2012, 222:567-573.
28. de Vries R., Groen A.K., Perton F.G., et al. Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis 2008, 196:733-741.
29. Yassine H.N., Belopolskaya A., Schall C., Stump C.S., Lau S.S., Reaven P.D. Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. Metab Clin Exp 2014, 63:727-734.
30. Nestel P., Hoang A., Sviridov D., Straznicky N. Cholesterol efflux from macrophages is influenced differentially by plasmas from overweight insulin-sensitive and -resistant subjects. Int J Obes 2012, 36:407-413.
31. Zhou H., Tan K.C.B., Shiu S.W.M., Wong Y. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy. Diabetes Metab Res Rev 2008, 24:617-623.
32. Kubota M., Nakanishi S., Hirano M., et al. Relationship between Serum Cholesterol Efflux Capacity and Glucose Intolerance in Japanese-Americans. J Atheroscler Thromb 2014, 21:1087-1097.
33. Mehta N.N., Li R., Krishnamoorthy P., et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012, 224:218-221.
34. Holzer M., Wolf P., Curcic S., et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 2012, 53:1618-1624.
35. Charles-Schoeman C., Lee Y.Y., Grijalva V., et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 2012, 71:1157-1162.
36. Ronda N., Favari E., Borghi M.O., et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2014, 73:609-615.
37. Hernáez Á., Fernández-Castillejo S., Farràs M., et al. Olive Oil Polyphenols Enhance High-Density Lipoprotein Function in Humans A Randomized Controlled Trial. Arterioscler Thromb Vasc Biol 2014.
38. Beulens J.W.J., Sierksma A., Van Tol A., et al. Moderate alcohol consumption increases cholesterol efflux mediated by ABCA1. J Lipid Res 2004, 45:1716-1723.
39. Buonacorso V., Nakandakare E.R., Nunes V.S., Passarelli M., Quintão E.C.R., Lottenberg A.M.P. Macrophage cholesterol efflux elicited by human total plasma and by HDL subfractions is not affected by different types of dietary fatty acids. Am J Clin Nutr 2007, 86:1270-1277.
40. Kralova Lesna I., Suchanek P., Kovar J., Stavek P., Poledne R. Replacement of dietary saturated FAs by PUFAs in diet and reverse cholesterol transport. J Lipid Res 2008, 49:2414-2418.
41. Ribeiro I.C.D., Iborra R.T., Neves M.Q.T.S., et al. HDL Atheroprotection by Aerobic Exercise Training in Type 2 Diabetes Mellitus. Med Sci Sports Exerc 2008, 40:779-786.
42. Blazek A., Rutsky J., Osei K., Maiseyeu A., Rajagopalan S. Exercise-mediated changes in high-density lipoprotein: Impact on form and function. Am Heart J 2013, 166:392-400.
43. Aicher B.O., Haser E.K., Freeman L.A., et al. Diet-induced weight loss in overweight or obese women and changes in high-density lipoprotein levels and function. Obesity (Silver Spring) 2012, 20:2057-2062.
44. Roe A., Hillman J., Butts S., et al. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS. J Clin Endocrinol Metab 2014, 99:E841-E847.
45. Cavallero E., Brites F., Delfly B., et al. Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles. Arterioscler Thromb Vasc Biol 1995, 15:2130-2135.
46. Brites F.D., Cavallero E., de Geitere C., et al. Abnormal capacity to induce cholesterol efflux and a new LpA-I pre-beta particle in type 2 diabetic patients. Clin Chim Acta 1999, 279:1-14.
47. Zhou H., Shiu S.W.M., Wong Y., Tan K.C.B. Impaired serum capacity to induce cholesterol efflux is associated with endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res 2009, 6:238-243.
48. Králová Lesná I., Suchánek P., Stávek P., Poledne R. May Alcohol-Induced Increase of HDL Be Considered as Atheroprotective?. Physiol Res 2010, 59:407-413.